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Abstract
Objective. To determine whether pre- and post-
operative administration of intravenous ibuprofen
(IV-ibuprofen) can signiﬁcantly decrease pain and
morphine use when compared with placebo in adult
orthopedic surgical patients.
Design. This was a multi-center, randomized,
double-blind placebo-controlled trial.
Setting. This study was completed at eight hospi-
tals; six in the United States and two in South Africa.
Patients. A total of 185 adult patients undergoing
elective orthopedic surgery.
Interventions. Patients were randomized to receive
either 800 mg IV-ibuprofen or placebo every 6 hours,
with the ﬁrst dose administered pre-operatively.
Additionally, all patients had access to intravenous
morphine for rescue.
Outcome Measures. Efficacy of IV-ibuprofen was
demonstrated by measuring the patient’s self
assessmentofpainusingavisualanalogscale(VAS;
assessed with movement and at rest) and a verbal
responsescale(VRS).Morphineconsumptionduring
the post-operative period was also assessed.
Results. In the immediate post-operative period,
there was a 25.8% reduction in mean area under the
curve-VAS assessed with movement (AUC-VASM) in
patients receiving IV-ibuprofen (P < 0.001); a 31.8%
reduction in mean AUC-VAS assessed at rest (AUC-
VASR; P < 0.001) and a 20.2% reduction in mean
VRS (P < 0.001) compared to those receiving
placebo. Patients receiving IV-ibuprofen used 30.9%
less morphine (P < 0.001) compared to those receiv-
ing placebo. Similar treatment emergent adverse
events occurred in both study groups and there
were no signiﬁcant differences in the incidence of
serious adverse events.
Conclusion. Pre- and post-operative administration
of IV-ibuprofen signiﬁcantly reduced both pain
and morphine use in orthopedic surgery patients in
this prospective randomized placebo-controlled
trial.
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Introduction
Opioids are considered the treatment cornerstone for
severe post-operative pain [1]. In the United States, more
than 60% of the patients who have experienced moderate
or severe post-operative pain have received morphine as
a post-operative pain therapy [2]. A multimodal approach
to pain management is an effective means of achieving
comprehensive pain relief, while minimizing the potential
for opioid-related adverse effects by lowering the total
dose of opioid that is required [3].
A previous randomized, placebo controlled trial in
surgical patients, including those undergoing orthopedic
procedures, evaluated pain reduction and the opioid
sparing effect of intravenous ibuprofen (IV-ibuprofen)
during multimodal post-operative pain management [4].
This trial demonstrated that 800 mg IV-ibuprofen dosed
every 6 hours produced a signiﬁcant reduction in pain and
morphine use in surgical patients [4].
Methods
This was a multi-center, randomized, double-blind,
placebo-controlled study of the safety and efﬁcacy of
IV-ibuprofen for post-operative pain following elective
knee or hip replacement, reconstruction or arthroplasty
with an anticipated need for post-operative hospitalization
and IV morphine analgesia for at least 28 hours. This
study was approved by institutional review boards
or independent ethics committees at all participa-
ting sites. Efﬁcacy was measured by comparing the
patients’ self-assessment of pain and morphine use in the
post-surgical period.
Study Design
Patients who met all of the inclusion criteria and did not
meet any exclusion criteria (Table 1) were consented and
randomized in a 1:1 ratio (treatment assignment was
blinded) to receive either 800 mg of IV-ibuprofen or
placebo (visually indistinguishable). The 800 mg dose, and
the dosing schedule (every 6 hours), was selected based
on results from previous clinical studies of IV-ibuprofen for
the management of post-operative pain in hospitalized
patients [4].
In previous clinical studies of IV-ibuprofen, the initial dose
was administered intra-operatively. However, the current
trial sought to determine if IV-ibuprofen would also have a
signiﬁcant effect on the onset of pain. Therefore, the ﬁrst
dose of study drug was administered prior to the surgical
procedure. The study drug was infused over 30 minutes
through either a peripheral or a central venous catheter.
After surgery, all patients had access to PCA morphine.
Previous clinical studies demonstrated that despite having
access to morphine, patients receiving IV-ibuprofen not
only used less morphine, but also reported lower pain
scores [4]. The placebo control was chosen to accurately
assess the treatment effect associated with IV-ibuprofen,
utilizing both pain scores and the morphine-sparing
model.
Patient Population and Interventions
The trial was conducted in an in-patient setting at a total of
eight surgical hospital sites. Six of the eight sites were in
the United States: Dekalb Medical Center (Decatur, GA),
Arkansas Surgical Hospital (North Little Rock, AR), Foun-
dation Surgical Hospital (Bellaire, TX), Memorial Hermann-
Memorial City Hospital (Houston, TX), Methodist Hospital
(Arcadia, CA), and Springhill Memorial Hospital (Mobile,
AL). Two of the eight sites were in South Africa: Johan-
nesburg General Hospital (Johannesburg, Gauteng, RSA)
and Eugene Marias Hospital (Pretoria, Gauteng, RSA).
Enrollment was open to adults between ages 18 and 80
years who were scheduled for elective hip or knee
replacement, reconstruction or arthroplasty, with an antici-
pated hospital stay and anticipated concomitant need for
IV morphine analgesia for at least 28 hours post-
procedure. Patients were required to weigh more than
30 kg, have adequate venous access as well as the ability
to perform a pain intensity report, and not have a narcotic
dependence or a known tolerance to opioids (Table 1).
Patients were randomized to receive either 800 mg of IV
ibuprofen or placebo and the clinical trial duration was 7
days (Figure 1). The ﬁrst dose of study drug was admin-
istered at the induction of anesthesia, prior to the surgical
procedure (Figure 1). Four subsequent doses of study
drug were to be administered every 6 hours over the next
24 hours (Figure 1). After the patient received ﬁve sched-
uled doses of study drug, additional doses could be
administered as needed every 6 hours through the 120-
hour treatment period (Figure 1).
Upon discharge from the operating room, all patients had
access to intravenous morphine via a PCA pump. Initial
settings were a 1 mg demand dose with a 5-minute
lockout. If adequate pain control was not achieved the
demand dose of morphine could be increased to 2 mg
every 5 minutes, and additional morphine could be admin-
istered at the treating physician’s discretion. However,
basal infusions of morphine were not allowed. A data
safety monitoring committee reviewed all serious adverse
events reported during the study.
All patients received general anesthesia using various
anesthetics such as propofol or a member of the ﬂurane
drug family along with fentanyl for intraoperative narcotic
maintenance (fentanyl dose was per the discretion of the
anesthesiologist). Intraoperative use of any other analge-
sics including nonsteroidal agents was prohibited.
Neuraxial anesthesia (local anesthetics and narcotics)
were prohibited. Single shot and catheter-based regional
techniques were also prohibited.
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The primary objective of this study was to determine the
efﬁcacy of IV-ibuprofen compared with placebo for the
treatment of surgical pain during hours 6–28 post-
operatively, demonstrated by patient self-assessment of
pain with movement (VASM), using a visual analog scale
(VAS). Secondary objectives included several efﬁcacy
measurements to help elucidate the analgesic effect of
perioperative IV ibuprofen in the 6–28 hour time period
Table 1 Inclusion and exclusion criteria
Inclusion Criteria
1. Scheduled for elective hip or knee replacement, reconstruction or arthroplasty surgery with anticipated need
for post-operative I.V. morphine analgesia with anticipated use of >28 hours.
2. Adequate IV access
3. Anticipated hospital stay >28 hours
Exclusion Criteria
1. Be unable to make a reliable self-report of pain intensity to pain relief
2. Less than 18 years of age
3. Greater than 80 years of age
4. Use of analgesics, muscle relaxants, NSAIDs and sedatives less than 12 hours prior to CTM administration
with the following exceptions: acetaminophen (paracetamol) can be administered until 6 hours prior to
surgery, tramadol can be administered until midnight the evening prior to surgery, muscle relaxants working at
the neuromuscular junction used for intubation and/or anesthesia administration for the surgical procedure
prior to CTM administration, and sedatives (i.e., midazolam) used as a co-induction agent for the surgical
procedure prior to CTM administration
5. Patients taking warfarin, lithium, combination of ACE-inhibitors and furosemide
6. Patients with anemia (active, clinically signiﬁcant anemia) and/or a history or evidence of asthma or heart
failure
7. History of allergy or hypersensitivity to any component of intravenous ibuprofen, aspirin (or aspirin related
products), NSAIDs, or COX-2 inhibitors
8. Pregnant or nursing
9. History of severe head trauma that required current hospitalization, intracranial surgery or stroke within the
previous 30 days, or any history of intracerebral arteriovenous malformation, cerebral aneurism or CNS mass
lesion
10. Weigh less than 30 kg
11. Have a history of congenital bleeding diathesis (e.g., hemophilia) or any active clinically signiﬁcant bleeding,
or have underlying platelet dysfunction including (but not limited to) idiopathic thrombocytopenic purpura,
disseminated intravascular coagulation, or congenital platelet dysfunction
12. Have GI bleeding that required medical intervention within the previous 6 weeks (unless deﬁnitive surgery has
been performed)
13. Have a platelet count less than 30,000 mm3 determined within the 28 days prior to surgery
14. Pre-existing dependence on narcotics or known tolerance to opioids
15. Inability to understand the requirements of the study, be willing to provide written informed consent (as
evidenced by signature on an informed consent document approved by an Institutional Review Board [IRB]),
and agree to abide by the study restrictions and to return for the required assessments
16. Refusal to provide written authorization for use and disclosure of protected health information
17. Be on dialysis, have oliguria or creatinine > 3.0 mg/dL
18. Inability to achieve hemostasis or inability to close surgical incision, prior to operating room discharge
19. Operative procedure includes organ transplant
20. Pre or intra-operative procedure utilized for the prevention of pre- or post-operative pain (i.e., epidural or
nerve blocks)
21. Be receiving full dose anticoagulation therapy or Activated Protein C within 6 hours before dosing
(Prophylaxis with subcutaneous heparin is acceptable)
22. Have received another investigational drug within the past 30 days
23. Be otherwise unsuitable for the study in the opinion of the investigator
* Use of anticoagulants for prevention of DVT’s was permitted.
NSAID = nonsteroidal anti-inﬂammatory drug; CTM = clinical trial material; ACE = angiotensin-converting enzyme; COX-2 =
cyclooxygenase 2; CNS = central nervous system.
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measured by the VAS assessed at rest (VASR), 2) pain
measured by the verbal rating scale (VRS), and 3) differ-
ences in post-operative morphine consumption between
groups.
Prior to the scheduled 6-hour post-operative pain assess-
ment, a VASM and VASR were performed as soon as the
patient was awake and alert enough to properly perform
the procedure. On average, patients were able to perform
this assessment at 2.81 hours post-operatively. An addi-
tional secondary endpoint (deemed early post-op pain)
examined the differences between treatment groups at
this time.
Pain assessments were performed at the following time
points: immediately following surgery as soon as the
patient was awake enough to comply with study proce-
dures, at hours 6, 8, 12, 16, 20, 24, 28, and then 2 hours
after any subsequent doses of study medication that was
administered in the 28–72 hours post-operative period.
Additionally, after the 28-hour mark, scheduled VAS
scores were obtained each day until the study drug was
discontinued.
The VAS used was a standard 100-mm scale. VRS pain
assessment measured a patient’s self-report of pain on a
numerical scale from 0 (no pain) to 4 (severe pain at rest
and with movement). Additional measurements of efﬁcacy
included in the study were incidence of treatment failure,
time to GI motility, time to resumption of ambulation, time
to resumption of liquid intake and solid diet, incidence of
opioid related side effects, and length of hospital stay.
Safety Assessments
The safety proﬁle of 800 mg IV-ibuprofen infused every 6
hours vs placebo was evaluated through comparison of
treatment-emergent adverse events, as well as vital signs,
clinical chemistry values, hematology and coagulation
values, and transfusion requirements. Investigators were
asked to report any adverse medical events (new events
or worsening conditions) that occurred during the seven
day study and to grade the event by intensity (mild, mod-
erate, severe), record action taken with the study drug,
causality to the study drug, required treatment, outcome,
and time of resolution. Vital signs and laboratory results
were monitored closely to investigate the effects of treat-
ment, including renal-related effects and any possible
impact on bleeding, during screening, at baseline, at
hours 1, 3, 6, 9, 12, 24 hours after study drug adminis-
tration, and daily through day 5 or discharge. Require-
ments for transfusions of blood products (including
packed red blood cells, fresh frozen plasma, and platelets)
were also collected. Clinical laboratory assessments
included clinical chemistry (sodium, potassium, chloride,
total carbon dioxide, glucose, blood urea nitrogen, crea-
tinine, total bilirubin, albumin, total protein, aspartate
aminotransferase, alanine aminotransferase, lactate dehy-
drogenase). Hematology and coagulation assessments
included white blood cell count and differential, hemat-
ocrit, hemoglobin, platelet count, activated partial throm-
boplastin time, and prothrombin time or INR. Lab results
were assessed during screening, baseline, and on study
days 1, 2, 3, and 5 or at discharge. Adverse event
monitoring continued through day 14. In the event that
a patient was discharged before the end of the study,
safety assessments were conducted by follow-up visit or
telephone.
Patients were also evaluated with a combined safety
assessment: 1) occurrence of diffuse pruritus; 2) occur-
rence of overt respiratory depression; 3) need for post-
operative urinary indwelling catheter (after initial removal of
surgical catheter); 4) incidence of post-operative vomiting
or need for anti-emetic medication; and 5) the Richmond
Agitation Sedation Scale. The initial Combined Safety
Assessment was performed following surgery upon rever-
sal of anesthesia, and then at post-operative hours 6, 8,
12, 16, 20, 24, and 28.
Analysis Methods
The study population consisted of patients who were
randomized and received at least one dose of study
medication.
A literature review of morphine dosing shows that there is
a correlation between dose and patient age and weight. In
an attempt to ensure a more balanced overall randomiza-
tion, treatment groups were stratiﬁed by age (45 and
>45–80 years) and weight (75 kg and >75 kg). Patients
greater than 80 years of age were excluded to reduce
variability because these patients generally require signiﬁ-
Figure 1 Study timeline.
Surgery
0          6          12          18          24       28    30  36
First 
Dose*
Primary Efficacy Evaluation Period
Dosing every 6 hours
Study Continuation
Doses administered every 6 hours (up to 120 hours) until resolution
of pain, removal of IV, or hospital discharge
Safety Evaluation Period (0-7 days)
*Saline Placebo or 800 mg IV-Ibuprofen
Study Hour
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obtained from an earlier study on IV-ibuprofen were used
in the sample size considerations. A sample size of 67 per
group provided 90% power to detect a 20% reduction in
pain-area under the curve (AUC) with movement with a
signiﬁcance level (alpha) of 0.05 using a two-sided two-
sample (independent) t-test. Sample size estimates were
done using NCSS/PASS software (NCSS, Kaysville, UT)
[6]. Analysis of the primary efﬁcacy parameters was
conducted on the study population.
The AUC from 6 to 28 hours for the VAS assessed with
movement (AUC-VASM [6–28]) was the primary efﬁcacy
endpoint, and the analysis of variance (ANOVA)w a s
applied. The primary model included factors for study
center, treatment group, age group, weight group and
their interactions. Interactions that were not statistically
signiﬁcant at the 20% level were removed from the model
before computing the test for treatment difference, while
interactions that were statistically signiﬁcant at the 20%
level were retained as alpha-level adjustments [7].
Frequency and percent of treatment failure was compared
across treatment groups using a Chi-square test, while the
time to treatment failure was evaluated using survival
methods. Median time to treatment failure was calculated
using the Kaplan–Meier approach and the treatment
groups were compared with a log-rank test.
Computation of the AUC measures utilized all available
information. Exact times of observations were imputed
whenever available. Since the trapezoidal rule was used to
compute the AUC, any absent scheduled observations
were estimated by linear interpolation from the observa-
tions on either side of the missing data point, utilizing
direct-likelihood mixed model repeated measures meth-
odology [8].
Adverse events were coded using MedDRA preferred ter-
minology and MedDRA system organ classiﬁcations, and
the adverse events were also coded as serious or non-
serious using FDA deﬁnitions.
Results
A total of 185 patients were enrolled at eight clinical sites
in the United States and South Africa. Table 2 presents the
demographics and characteristics for the study popula-
tion (all randomized patients who received at least one
dose of study medication). The mean age for all patients
w a s6 1( 10.2 SD) years, and the ages ranged from a
minimum of 24 to a maximum of 80 years. There was no
Table 2 Demographics and baseline characteristics
Placebo Intravenous ibuprofen Total
n = 86 n = 99 n = 185
Age
Mean (SD) 60 (9.9) 62 (10.3) 61 (10.2)
Age category
<45 years old 6 (7%) 3 (3%) 9 (5%)
45–80 years old 80 (93%) 96 (97%) 176 (95%)
Gender
Male 31 (36%) 34 (34%) 65 (35%)
Female 55 (64%) 65 (66%) 120 (65%)
Race
Caucasian 60 (70%) 76 (77%) 136 (74%)
Black 24 (28%) 19 (19%) 43 (23%)
Hispanic 1 (1%) 3 (3%) 4 (2%)
Asian 0 1 (1%) 1 (<1%)
Other 1 (1%) 0 1 (<1%)
Height (cm)
Mean (SD) 168.0 (11.18) 167.5 (10.22) 167.7 (10.65)
Weight (kg)
Mean (SD) 96.6 (23.81) 89.2 (20.78) 92.6 (22.49)
Surgical procedure
Hip replacement 14 (16%) 26 (26%) 40 (22%)
Hip reconstruction 0 0 0
Hip arthroplasty 5 (6%) 11 (11%) 16 (9%)
Knee replacement 50 (58%) 42 (42%) 92 (50%)
Knee reconstruction 0 0 0
Knee arthroplasty 17 (20%) 19 (19%) 36 (19%)
Other: surgery cancelled 0 1 (1%) 1 (<1%)
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IV-ibuprofen 62 (10.3 SD); placebo 60 (9.9 SD).
Of the 185 patients enrolled, 65 (35%) were male and 120
(65%) were female. There was no difference in gender
between treatment groups. In the study population, 136
participants (74%) were Caucasian, 43 (23%) were Black,
4 (2%) were Hispanic, 1 (<1%) was Asian, and 1 (<1%)
indicated “Other” for race.
The mean height for all patients was 167.7 cm (10.7
SD), and there was no difference in height between treat-
ment groups. The mean weight for all patients was
92.6 kg (22.5 SD). Weight ranged from a minimum of
55.0 kg to a maximum of 183.0 kg. There was a signiﬁ-
cant difference in weight between treatment groups:
800 mg IV-ibuprofen 89.2 (20.8 SD); placebo 96.6
(23.8 SD) (P = 0.025).
Of the 185 patients enrolled, 92 (50%) underwent a knee
replacement, 40 (22%) underwent a hip replacement, 36
(19%) underwent a knee reconstruction, and 16 (9%)
underwent a hip reconstruction and one (<1%) had the
surgery cancelled.
Clinical centers were asked to perform a baseline physical
examination and to indicate whether body systems were
normal or abnormal. Overall, the participants in this study
had few abnormalities at baseline, except for the indica-
tion for surgery.
There was no difference in the number of doses adminis-
tered between the IV-ibuprofen and the placebo treatment
groups, with a median of ﬁve doses (range = 1t o1 3
doses). The mean number of doses for the IV-ibuprofen
treatment group was 6 doses (SD 2.0), and 5 doses
(SD 1.4) for the placebo treatment group.
Efﬁcacy
The primary objective of this study was to determine the
efﬁcacy of IV-ibuprofen compared with placebo for the
treatment of post-operative surgical pain during hours
6–28 demonstrated by patient self-assessment of pain
with movement, using a VAS. During the 6–28-hour
post-operative period, when compared to patients
receiving placebo, patients receiving IV-ibuprofen
experienced:
• 25.8% decrease in the mean AUC-VASM (P < 0.001)
(Figure 2 and Table 3).
• 31.8% decrease in the mean AUC-VASR (P < 0.001)
(Figure 3 and Table 3).
• 20.2% decrease in the mean AUC-VRS (P < 0.001)
(Table 4).
• 30.9% decrease in mean morphine consumption
(P < 0.001) (Table 5).
The secondary endpoint evaluating early post-operative
pain revealed that patients receiving a pre-operative dose
of IV-ibuprofen experienced a 13.9% decrease in the
mean VASM (P = 0.003) and a 15.8% decrease in the
mean VASR (P = 0.012) following surgery (mean 2.81
hours after surgery) when compared with placebo (Table 6
and Figures 2 and 3).
Additional measurements of efﬁcacy included the inci-
dence of treatment failure, time to GI motility, time to
resumption of ambulation, time to resumption of liquid
intake and solid diet, incidence of opioid related side
Figure 2 VASM scores, over
time, post surgery-pain with
movement was assessed by
VAS at the ﬁrst immediate post-
operative opportunity (mean
2.81 hours) out to study hour 28
in the IV-ibuprofen and placebo
treatment groups. Error bars
denote SEM. Time (hours)
V
A
S
 
(
m
m
)
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sample size, there were no signiﬁcant differences between
treatment groups for any of these secondary efﬁcacy
measurements.
Efﬁcacy data were collected past study hour 28; however,
more than 80% of the patients had discontinued study
medication by the 38 hour time point making any efﬁcacy
comparisons for the later time points statistically under-
powered. Patients discontinued the study medication
when their IV was removed or they were converted to oral
analgesics.
Safety
All 185 patients who were enrolled in the study and
received at least one dose of study medication were
included in the safety analysis population. As was previ-
Table 3 Summary of Pain Measured by VAS (AUC-VAS; with movement and at rest)
AUC Placebo + Morphine (n = 86) 800 mg + Morphine (n = 99)
With movement
6–28 hours (post-operative period)
Mean (SD) 1,307.8 (388.7) 970.1 (422.2)
LS Means (SE) 1,326.1 (82.0) 1,005.0 (81.5)
Median 1,304.6 946.2
LS means difference (95% CI) -321.1 (-436.7, -205.4)
P value vs Placebo* <0.001
At rest
6–28 hours (post-operative period)
Mean (SD) 910.9 (424.3) 620.8 (401.0)
LS means (SE) 997.0 (83.6) 728.0 (83.0)
Median 905.1 566.0
LS means difference (95% CI) -269.0 (-386.8, -151.2)
P value vs Placebo* <0.001
* The analysis is based on a linear ANCOVA model with ﬁxed effects for age group, weight group, randomization center, and
treatment group. The P values and 95% conﬁdence intervals are based on the difference in the LS Means from the ﬁnal ANCOVA
model. LS = least squares; VAS = visual analog scale; ANCOVA = analysis of covariance; AUC = area under the curve.
Figure 3 VASR scores, over
time, post surgery-pain at rest
was assessed by VAS at the ﬁrst
immediate post-operative
opportunity (mean 2.81 hours)
out to study hour 28 in the
IV-ibuprofen and placebo treat-
ment groups. Error bars denote
SEM. Time (hours)
V
A
S
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m
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doses administered between the IV-ibuprofen and the
placebo groups. All patients had study medication
stopped prior to treatment day 5, primarily due to the IV
access being discontinued.
Treatment-emergent adverse events (AEs) and serious
adverse events (SAES) were reported in 164 (89%) of the
185 patients (Table 7). In the IV-ibuprofen group, 90 of 99
(91%) patients experienced treatment-emergent AEs; 45
were of mild intensity, 39 were of moderate intensity, and
6 were severe. In the placebo group, 74 of 86 (86%)
patients experienced treatment-emergent AEs; 36 were of
mild intensity, 37 were of moderate intensity, and 1 was
severe. There was not a statistically signiﬁcant difference
between treatment groups (P = 0.356).
Nine subjects (5%) experienced a total of 11 SAEs. The
relationship of SAEs to study drug was coded by the
investigators as related, not related, and unknown or
uncertain. In the IV-ibuprofen group, 6 of 99 (6%) partici-
pants experienced eight SAEs. In the placebo group, 3 of
86 (3%) participants experienced three serious adverse
events. Of these 11 serious events, none were coded as
related; four were coded as not related; and seven as
unknown or uncertain. There was not a statistically signiﬁ-
cant difference in the number of patients experiencing
SAEs when comparing the IV-ibuprofen treated patients
with the placebo treated patients (P = 0.507).
The packed red blood cell transfusions between study day
0 and 5 did not differ between the IV-ibuprofen group, with
12 of 99 (12%) requiring transfusions, and the placebo
group, with 9 of 86 (10%) patients receiving packed red
blood cells. There were no patient deaths during the 14
day study. While patients were excluded if they were
receiving full dose anticoagulation therapy, approximately
19% of the patients enrolled in the study were receiving
partial anticoagulation therapy in the 12 hours preceding
surgery and 60% received anticoagulation therapy follow-
ing surgery.
AEs and clinical laboratory assessments commonly asso-
ciated with oral ibuprofen were speciﬁcally examined,
including hypertension, bleeding and bruising related
events (even if not the primary surgical site), and abnormal
laboratory measurements. In AEs experienced by at least
three subjects, there were no clinically signiﬁcant differ-
ences in the incidence of known AEs associated with oral
ibuprofen in the IV-ibuprofen group when compared to
placebo. In the treatment-emergent AEs experienced by
at least three patients, there were signiﬁcantly more
Table 4 Summary of pain measured by verbal response scale
AUC Placebo (N = 80) 800 mg (N = 99)
6–28 hours (post-operative period)
Mean (SD) 49.5 (18.2) 39.5 (17.1)
LS means (SE) 51.8 (3.7) 43.2 (3.6)
Median 50.7 38.0
LS means difference (95% CI) -8.6 (-13.6, -3.6)
P value vs Placebo* <0.001
* The analysis is based on a linear ANCOVA model with ﬁxed effects for age group, weight group, randomization center, and
treatment group. The p-values and 95% conﬁdence intervals are based on the difference in the LS Means from the ﬁnal ANCOVA
model.
LS = least squares; AUC = area under the curve; ANCOVA = analysis of covariance.
Table 5 Summary of reduction in morphine consumption (mg morphine sulfate)
Morphine requirement Placebo (N = 86) 800 mg (N = 99)
6–28 hours (post-operative period)
N8 5 9 7
Mean (SD) 59.5 (29.9) 41.1 (27.3)
LS means (SE) 60.9 (5.7) 44.3 (5.7)
Median 58.0 38.0
LS means difference (95% CI) -16.6 (-24.7, -8.4)
P value vs Placebo* <0.001
* The analysis is based on linearANCOVAmodel with ﬁxed effects for age group, weight group, randomization center, and treatment
group. The p-values and 95% conﬁdence intervals are based on the difference in the LS Means from the ﬁnal ANCOVA model.
LS = least squares; ANCOVA = analysis of covariance.
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iting (P = 0.031), and signiﬁcantly more patients in the
placebo group who experienced dyspepsia (P = 0.045)
(Table 7).
Discussion
Pain is the greatest concern of patients before surgery [9].
Administered orally, ibuprofen is effective in blocking pain
and inﬂammation, in part by preventing the production of
prostaglandins. An intravenous formulation of ibuprofen
has the potential to arrest the inﬂammatory cascade trig-
gered by surgical procedures and to reduce or prevent the
development of post-operative pain. A previous random-
ized, placebo controlled trial in surgical patients, including
those undergoing orthopedic procedures, evaluated pain
reduction and the opioid sparing effect of IV-ibuprofen
during multimodal post-operative pain management and
demonstrated that 800 mg IV-ibuprofen dosed every 6
hours produced a signiﬁcant reduction in pain and mor-
phine use in surgical patients [4]. This study involves the
ﬁrst report of pre-operative administration of IV-ibuprofen.
NSAIDs carry warnings for cardiovascular and gas-
trointestinal risk and should be used with caution in
patients with congestive heart failure, renal impairment, a
risk for blood clots, and/or a history of ulcers or gas-
trointestinal bleeding. The only other available injectable
NSAID, ketorolac, includes additional warnings for use in
geriatric patients and is contraindicated for use in children
[10]. Additionally, it carries a black box warning against
pre-operative administration, and according to the
package insert, can only be administered for 5 days or
less [10]. Therefore, the introduction of an NSAID that can
be used safely prior to surgery adds another therapeutic
modality to treat post-operative pain.
IV-ibuprofen, 800 mg administered every 6 hours starting
with the onset of anesthesia in orthopedic surgery
patients, reduced both pain and morphine consumption
Table 6 Summary of pain measured by VAS in immediate post-OP period
VAS-immediately post-surgery Placebo (N = 86) 800 mg (N = 99)
With movement
N8 3 9 6
Mean (SD) 80.4 (22.4) 69.2 (29.3)
LS means (SE) 84.4 (5.2) 73.4 (5.0)
Median 88.0 73.5
LS means difference (95% CI) -11.0 (-18.2, -3.8)
P value vs Placebo* 0.003
At rest
N8 3 9 6
Mean (SD) 69.8 (29.0) 58.8 (31.5)
LS means (SE) 75.3 (6.0) 64.6 (5.8)
Median 79.0 57.0
LS means difference (95% CI) -10.7 (-19.0, -2.4)
P value vs Placebo* 0.012
* The analysis is based on a linear ANCOVA model with ﬁxed effects for age group, weight group, randomization center, and
treatment group. The p-values and 95% conﬁdence intervals are based on the difference in the LS Means from the ﬁnal ANCOVA
model.
LS = least squares; ANCOVA = analysis of covariance.
Table 7 Treatment emergent adverse events and the types of adverse events that differed signiﬁcantly
between treatment groups
Number of patients experiencing at
least one adverse event
Placebo
(n = 86)
800 mg
IV-Ibuprofen
(n = 99)
Safety
population
(n = 185) P value
74 (86%) 90 (91%) 164 (89%) 0.356
Adverse events that differed signiﬁcantly between treatment groups
Type of adverse event n % n % N %
Vomiting 12 (14%) 27 (27%) 39 (21%) 0.031
Dyspepsia 4 (5%) 0 0 4 (2%) 0.045
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placebo, patients receiving 800 mg IV-ibuprofen experi-
enced less pain beginning in the early post-operative
period and continuing at least through hour 28. There was
a signiﬁcant reduction in pain with movement and at rest
with IV-ibuprofen as measured by the AUC-VAS during the
6–28-hour post-operative period. There was also a signiﬁ-
cant reduction in mean morphine consumption in the
6–28-hour post-operative period in patients receiving
IV-ibuprofen.
The safety analysis encompassed all 185 patients that
participated in the study, 164 of which experienced treat-
ment emergent-AEs (serious and nonserious). There was
no difference in the general incidence of AEs between the
IV-ibuprofen and placebo treatment groups. Events
related to bleeding and coagulation times, and transfusion
requirements, did not differ between the two groups.
There were no deaths reported in this study. There were a
total of 11 SAEs occurring in nine patients, with no sta-
tistically signiﬁcant difference in the incidence of SAEs
between the patients receiving placebo and the patients
receiving IV-ibuprofen. The SAEs were consistent with
those typically observed in patients undergoing surgery
and treated with anesthesia and morphine.
Conclusions
Pre- and post-operative administration of IV-ibuprofen sig-
niﬁcantly reduced both pain and morphine use in ortho-
pedic surgery patients in this prospective randomized
controlled trial. The 800 mg dose provided patients with
analgesic beneﬁt and narcotic reduction. Post-operative
pain control protocols can now consider inclusion of
IV-ibuprofen as an option to offer patients a signiﬁcant
analgesic beneﬁt while reducing the risks associated with
morphine administration.
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